Floatz logo

rc48-adc

Squamous Esophageal Carcinoma

SOLTI Breast Cancer Research Groupantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Squamous Esophageal Carcinoma cohort.

Asset / SponsorPhaseRating
Tislelizumab
SOLTI Breast Cancer Research Group
Phase 2CCC
Pyrotinib
SOLTI Breast Cancer Research Group
Phase 2CCC

Same molecule, other indications

rc48-adc is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →